Long-term levetiracetam monotherapy for partial epilepsy in adults
https://doi.org/10.14412/2074-2711-2012-2498
Abstract
The paper analyzes the efficiency of 3-year monotherapy with levetiracetam (LTC) (keppra) in 143 patients aged 16—73 years with partial epilepsy. LTC was used as first-line monotherapy in 71 patients (Group 1); second- or third-line monotherapy in 72 patients (Group 2) when the first-line therapy with antiepileptic drugs was insufficiently effective or poorly tolerated.
The percentage of treatment retention is an integral index of the cumulative efficiency of therapy (remission + a >50% reduction in seizure frequency) minus the percent of drug discontinuation for various reasons over a given period of time. In Group 1, the retention rate was 90.1, 87.3, and 83.1 in the first, second, and third year and in Group 2, that was 75.0, 70.8, and 69.4%, respectively.
LTC was found to be well tolerated. Its discontinuation because of its adverse reactions at one-year follow-up was noted in less than 5.6% (Group 1) and 8.2% (Group) of the patients. The findings suggest that the long-term use of keppra is promising in therapy for partial epilepsy.
About the Authors
P. N. Vlasov
Department of Nervous Diseases, Therapeutic Faculty, Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
V. A. Karlov
Department of Nervous Diseases, Therapeutic Faculty, Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
E. G. Komelkova
Department of Nervous Diseases, Therapeutic Faculty, Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Z. S. Shakhabasova
Department of Nervous Diseases, Therapeutic Faculty, Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
References
1. <div><p>Карлов В.А. Эпилепсия у детей и взрослых, женщин и мужчин. М.: Медицина, 2010;718 с.</p><p>Landmark J.C., Patsalos P.N. Drug interactions involving the new second- and third generation antiepileptic drugs. Expert Rev Neurother 2010;10:119–40.</p><p>Trinka E., Van Paesschen W., Hallstrom Y. et al. The komet study: an open label, randomized, parallel-group trial comparing the efficacy and safety of levetiracetam with sodium valproate and carbamazepine as monotherapy in subjects with newly diagnosed epilepsy. Epilepsia 2009;50(Suppl. 2):006.</p><p>Simister R.J, Sander J.W., Koepp M.J. Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behavior 2007;10:336–9.</p><p>Kuba R., Novotna I., Brazdil M. et al. Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. Acta Neurol Scand 2010;121:83–8.</p><p>Карлов В.А., Власов П.Н. Результаты двухлетнего применения кеппры для лечения эпилепсии у взрослых. Журн неврол и психиатр 2006;106(7):24–30.</p><p>Harden C. Safety profile of levetiracetam. Epilepsia 2001;42(Suppl. 4):36–9.</p><p>French J., Edrich P., Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic druq. Epilepsy Res 2001;47:77–90.</p><p>Berg K., Samren E.B., Oppen A.C. et al. Levetiracetam use and pregnancy outcome. Reprod Toxicol 2005;20:175–8.</p><p>Hunt S., Irwin B., Waddell R. et al. Levetiracetam therapy in human pregnancy updated experience from the UK epilepsy and pregnancy register. Epilepsia 2009;50(Suppl. 4):003.</p><p>Tomson T., Palm R., Kallen K. et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period and lactation. Epilepsia 2007; 48:1111–6.</p></div><br />
Review
For citations:
Vlasov PN, Karlov VA, Komelkova EG, Shakhabasova ZS. Long-term levetiracetam monotherapy for partial epilepsy in adults. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(1S):43-47. (In Russ.) https://doi.org/10.14412/2074-2711-2012-2498
Views:
945
Email this article 